Today's Low
₹ 755.40
Today's High
₹ 780.00
52 Weeks Low
₹ 370.00
52 Weeks High
₹ 546.50
Lower
₹ 675.45
Upper
₹ 825.55
Glenmark Life Sciences Limited develops, manufactures, and supplies non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for cardiovascular diseases; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for central nervous system diseases; Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for diabetes; and Etoricoxib and Lornoxicam for pain management. It also provides Atovaquone, Voriconazole, Mirabegron, Desloratadine, Esomeprazole Magnesium, Adapalene, and Fluconazole gastro-intestinal disorders, anti-infective, respiratory, anti-emetic, and other therapeutic areas. In addition, the company offers contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited is a subsidiary of Glenmark Pharmaceuticals Limited.
No of shares Outstanding
EPS-TTM
Face Value
Book Value
Net Asset Value
ROE
ROA
ROCE
Dividend Yield
Total Debt
Sales Growth
PAT Growth
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
---|---|---|---|---|---|---|
Total Current Assets | 2,368.7 | 2,127.4 | 1,622.5 | 1,160.1 | 930.7 | 0.1 |
Total Non-Current Assets | 851.8 | 706.4 | 598.0 | 565.5 | 544.7 | 0.0 |
Total Assets | 3,220.5 | 2,833.8 | 2,220.6 | 1,725.6 | 1,475.4 | 0.1 |
Total Current Liabilities | 1,022.8 | 746.8 | 1,444.9 | 1,307.5 | 1,380.4 | 1.5 |
Total Non-Current Liabilities | 59.5 | 32.7 | 22.9 | 16.5 | 6.9 | 0.0 |
Shareholder's Funds | 2,138.2 | 2,054.3 | 752.8 | 401.7 | 88.1 | -1.4 |
Total Liabilities | 3,220.5 | 2,833.8 | 2,220.6 | 1,725.6 | 1,475.4 | 0.1 |
The Industry Quick Ratio stands at 1.77, vs the Quick Ratio of 1.73, which results in a Negative aspect.
The Industry Current Ratio stands at 2.53, vs the Current Ratio of 2.32, which results in a Negative aspect.
The Industry Debt to Equity Ratio stands at 0.20, vs the Debt to Equity Ratio of 0.00, which results in a Positive aspect.
The Industry Price to BV stands at 6.01, vs the Price to BV of 3.92, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
---|---|---|---|---|---|---|
Total Income | 2,161.2 | 2,123.2 | 1,885.2 | 1,537.3 | 886.4 | 0.3 |
Total Expenditure | 1,518.9 | 1,507.2 | 1,294.1 | 1,065.4 | 639.3 | 0.3 |
Operating Profit(Excl OI) | 671.3 | 630.8 | 591.9 | 484.0 | 248.2 | 0.0 |
Add: Other Income | 29.0 | 14.7 | 0.8 | 12.0 | 1.0 | 0.0 |
Operating Profit | 671.3 | 630.8 | 591.9 | 484.0 | 248.2 | 0.0 |
Less: Interest | 0.6 | 28.0 | 87.6 | 33.5 | 0.6 | 0.0 |
PBDT | 670.7 | 602.8 | 504.3 | 450.4 | 247.6 | 0.0 |
Less: Depreciation Amortization | 42.1 | 37.9 | 33.4 | 29.4 | 19.3 | 0.0 |
PBT & Exceptional Items | 628.6 | 564.9 | 470.9 | 421.1 | 228.3 | 0.0 |
Less: Exceptional Income Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit Before Tax | 628.6 | 564.9 | 470.9 | 421.1 | 228.3 | 0.0 |
Less: Taxation | 161.7 | 146.2 | 119.4 | 108.0 | 32.7 | 0.4 |
Profit After Tax | 467.0 | 418.7 | 351.6 | 313.1 | 195.6 | -0.4 |
Earnings Per Share | 3.8 | 3.4 | 3.3 | 2.9 | 1.8 | -0.8 |
The Industry PAT Growth stands at 41.10, vs the PAT Growth of 11.52, which results in a Negative aspect.
The Industry Dividend Yield stands at 0.60, vs the Dividend Yield of 2.62, which results in a Positive aspect.
The Industry PAT Margin stands at 9.68, vs the PAT Margin of 21.49, which results in a Positive aspect.
The Industry PE Ratio stands at 42.40, vs the PE Ratio of 18.93, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
---|---|---|---|---|---|---|
Profit Before Tax | 628.6 | 564.9 | 470.9 | 421.1 | 228.3 | 0.0 |
Tax Paid | -153.6 | -138.2 | -108.6 | -92.5 | -23.5 | 0.0 |
Adjustment | 35.3 | 71.0 | 133.3 | 56.7 | -101.1 | 0.0 |
Changes In Working Capital | 628.6 | 564.9 | 470.9 | 421.1 | 228.3 | 0.0 |
Cash Flow after changes in Working Capital | 467.0 | 735.8 | 496.7 | 287.5 | 33.9 | -0.5 |
Cash Flow from Operating Activities | 313.4 | 597.6 | 388.1 | 195.0 | 10.4 | -0.5 |
Cash Flow from Investing Activities | -154.1 | -122.2 | -68.7 | -50.5 | -8.9 | 0.0 |
Cash Flow from Financing Activities | -387.6 | -78.8 | -213.8 | -136.6 | 0.5 | 0.5 |
Net Cash Inflow / Outflow | -228.3 | 396.6 | 105.6 | 7.9 | 2.0 | 0.0 |
Opening Cash & Cash Equivalents | 512.2 | 115.6 | 10.0 | 2.1 | 0.0 | 0.0 |
Closing Cash & Cash Equivalent | 283.8 | 512.2 | 115.6 | 10.0 | 2.1 | 0.0 |
The Industry PFCF Ratio stands at 37.73, vs the PFCF Ratio of 33.81, which results in a Negative aspect.
The Industry PCF RATIO stands at 27.04, vs the PCF RATIO of 15.31, which results in a Negative aspect.
Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 5,728.0 | 5,953.6 | 5,784.5 | 6,213.2 | 5,407.3 | 5,093.0 | 4,898.7 | 5,140.6 | 5,225.0 | 5,617.6 | 5,249.0 |
Total Income | 5,745.0 | 6,007.3 | 5,803.0 | 6,241.6 | 5,473.4 | 5,193.2 | 4,993.6 | 5,191.5 | 5,260.3 | 5,638.5 | 5,288.8 |
Total Expenditure | 4,002.5 | 4,282.8 | 3,852.9 | 4,148.9 | 3,952.8 | 3,656.6 | 3,431.0 | 3,718.5 | 3,764.4 | 3,944.2 | 3,644.5 |
PBIDT (Excl OI) | 1,725.6 | 1,670.8 | 1,931.6 | 2,064.3 | 1,454.6 | 1,436.4 | 1,467.7 | 1,422.1 | 1,460.6 | 1,673.4 | 1,604.5 |
Other Income | 16.9 | 53.7 | 18.5 | 28.4 | 66.1 | 100.2 | 94.9 | 51.0 | 35.3 | 20.9 | 39.9 |
Operating Profit | 1,742.5 | 1,724.5 | 1,950.1 | 2,092.7 | 1,520.6 | 1,536.6 | 1,562.6 | 1,473.1 | 1,496.0 | 1,694.3 | 1,644.3 |
Interest | 3.9 | 4.0 | 4.0 | 1.2 | 1.6 | 1.3 | 1.4 | 1.3 | 0.6 | 72.3 | 205.5 |
Exceptional Items | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
PBDT | 1,738.6 | 1,720.5 | 1,946.2 | 2,091.5 | 1,519.0 | 1,535.3 | 1,561.3 | 1,471.8 | 1,495.4 | 1,622.0 | 1,438.8 |
Depreciation | 131.8 | 131.3 | 126.1 | 115.2 | 107.6 | 99.4 | 98.8 | 95.5 | 97.4 | 96.7 | 89.2 |
Profit Before Tax | 1,606.8 | 1,589.3 | 1,820.0 | 1,976.3 | 1,411.4 | 1,435.9 | 1,462.5 | 1,376.3 | 1,398.0 | 1,525.4 | 1,349.7 |
Tax | 419.2 | 401.9 | 465.5 | 512.7 | 361.5 | 367.1 | 375.1 | 387.3 | 360.9 | 373.3 | 340.5 |
Provisions and contingencies | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit After Tax | 1,187.7 | 1,187.4 | 1,354.5 | 1,463.6 | 1,049.9 | 1,068.8 | 1,087.3 | 989.0 | 1,037.1 | 1,152.0 | 1,009.1 |
Net Profit | 1,187.7 | 1,187.4 | 1,354.5 | 1,463.6 | 1,049.9 | 1,068.8 | 1,087.3 | 989.0 | 1,037.1 | 1,152.0 | 1,009.1 |
ADDITIONAL INFOS: | |||||||||||
Equity Capital | 245.1 | 245.1 | 245.1 | 245.1 | 245.1 | 245.1 | 245.1 | 245.1 | 245.1 | 245.1 | 215.6 |
Reserves | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
EPS | 9.7 | 9.7 | 11.1 | 11.9 | 8.6 | 8.7 | 8.9 | 8.1 | 8.7 | 9.8 | 9.4 |
Operating Profit Margin | 30.4 | 29.0 | 33.7 | 33.7 | 28.1 | 30.2 | 31.9 | 28.7 | 28.6 | 30.2 | 31.3 |
Net Profit Margin | 20.7 | 19.9 | 23.4 | 23.6 | 19.4 | 21.0 | 22.2 | 19.2 | 19.8 | 20.5 | 19.2 |
The Industry Net Sales Growth stands at 10.00, vs the Net Sales Growth of 1.79, which results in a Negative aspect.
The Industry Mcap Growth stands at -4.23, vs the Mcap Growth of -14.68, which results in a Negative aspect.
Type | Classic | Woodie | Camarilla |
---|---|---|---|
R4 | 954.15 | 1,011.38 | 853.23 |
R3 | 911.10 | 919.35 | 834.09 |
R2 | 868.05 | 872.18 | 827.71 |
R1 | 841.50 | 849.75 | 821.33 |
Pivot | 798.45 | 802.58 | 798.45 |
S1 | 771.90 | 780.15 | 808.57 |
S2 | 728.85 | 732.98 | 802.19 |
S3 | 702.30 | 710.55 | 795.81 |
S4 | 675.75 | 593.78 | 776.67 |
(All Values are in INR)
1 Day
1 Week
1 Month
Stoch RSI
0.00
Bullish
RSI
36.31
Neutral
ROC
-2.55
Bearish
UltimateOscillator
59.38
Neutral
Williams Indicator
-72.26
Neutral
CCI Indicator
-54.73
Neutral
MACD
-2,328.61
Bearish
Stochastic Indicator
56.02
Neutral
ATR
29.12
Low Volatility
Ex-Date | Ratio | Record Date |
---|
Ex-Date | Ratio | Record Date |
---|---|---|
Announcement Date | Dividend Amount | Dividend Percentage of FV | Dividend Type |
---|---|---|---|
17-10-2023 | 22.50 | 1125 | Interim |
24-03-2023 | 21.00 | 1050 | Interim |
22-11-2021 | 10.50 | 525 | Interim |
Date Of Conduct | Board Meeting Details |
---|---|
25-04-2024 | Audited Results |
23-01-2024 | Quarterly Results |
20-10-2023 | Quarterly Results |
09-10-2023 | Interim Dividend |
21-07-2023 | Quarterly Results |
27-04-2023 | Audited Results |
16-03-2023 | Interim Dividend |
27-01-2023 | Quarterly Results |
21-10-2022 | Quarterly Results |
04-08-2022 | Quarterly Results |
20-04-2022 | Audited Results & Final Dividend |
08-02-2022 | Quarterly Results |
10-11-2021 | Quarterly Results |